https://www.nasdaq.com/press-release/biocardia-establishes-new-manufacturing-facility-to-enable-its-cell-therapy-product
https://www.nasdaq.com/press-release/biocardia-reports-third-quarter-2021-financial-results-and-business-highlights-2021
https://www.nasdaq.com/press-release/biocardia-to-release-third-quarter-2021-financial-results-november-10-2021-2021-11-08
https://www.nasdaq.com/press-release/biocardia-announces-first-patient-treated-in-cardiamp-cell-therapy-trial-for-chronic
https://www.nasdaq.com/press-release/biocardia-issued-new-u.s.-patent-for-technology-that-enhances-control-for
https://www.nasdaq.com/press-release/biocardia-announces-first-cross-over-patient-treated-in-cardiamp-cell-therapy-heart
https://www.nasdaq.com/press-release/biocardia-announces-participation-at-the-a.g.p.-biotech-specialty-pharma-conference
https://www.nasdaq.com/press-release/cardiamp-cell-therapy-heart-failure-trial-to-be-featured-in-two-presentations-at
https://www.nasdaq.com/press-release/biocardia-announces-participation-at-the-h.c.-wainwright-23rd-annual-global
https://www.nasdaq.com/press-release/keynotes-educational-panels-and-60-companies-to-present-at-the-snn-network-summer
https://www.nasdaq.com/press-release/biocardia-to-participate-in-upcoming-investor-conferences-2021-08-13
https://www.nasdaq.com/press-release/biocardia-reports-second-quarter-2021-financial-results-and-business-highlights-2021
https://www.nasdaq.com/press-release/biocardia-to-participate-in-a-fireside-chat-at-the-btig-virtual-biotechnology
https://www.nasdaq.com/press-release/biocardia-announces-japanese-patent-on-imaging-system-for-targeting-cardiac-therapies
https://www.nasdaq.com/press-release/biocardia-announces-fourth-positive-dsmb-review-and-recommendation-to-continue-phase
https://www.nasdaq.com/press-release/biocardia-to-present-cardiamp-cell-therapy-clinical-trial-data-at-european-society-of
https://www.nasdaq.com/press-release/biocardia-announces-european-patent-office-decision-to-grant-patent-on-autologous
https://www.nasdaq.com/press-release/biocardia-to-be-added-to-the-russell-microcapr-index-2021-06-14
https://www.nasdaq.com/press-release/biocardia-to-present-at-the-ld-micro-virtual-invitational-conference-on-june-8-2021
https://www.nasdaq.com/press-release/biocardia-reports-first-quarter-2021-financial-results-and-business-highlights-2021
https://www.nasdaq.com/press-release/biocardia-signs-agreement-with-leading-japanese-biotechnology-company-for-catheter
https://www.nasdaq.com/press-release/biocardia-reports-2020-financial-results-and-recent-business-highlights-2021-03-30
https://www.nasdaq.com/press-release/biocardia-to-present-at-maxim-groups-inaugural-emerging-growth-virtual-conference
https://www.nasdaq.com/press-release/biocardia-signs-agreement-with-leading-japanese-pharmaceutical-company-for-catheter
https://www.nasdaq.com/press-release/biocardia-announces-clinical-leadership-changes-2021-02-17
https://www.nasdaq.com/press-release/biocardia-update-on-cell-therapy-product-development-and-2021-milestones-2021-02-02
https://www.nasdaq.com/press-release/accomplished-biotech-executive-krisztina-zsebo-ph.d.-joins-biocardias-board-of
https://www.nasdaq.com/press-release/biocardia-issued-new-u.s.-patent-for-technology-that-enhances-control-for-cardiac
https://www.nasdaq.com/press-release/biocardia-announces-positive-dsmb-review-and-recommendation-to-continue-phase-iii
https://www.nasdaq.com/press-release/biocardia-inc.-announces-%2410.5-million-registered-direct-offering-priced-at-the
https://www.nasdaq.com/press-release/biocardia-inc.-announces-%248.5-million-registered-direct-offering-priced-at-the-market
https://www.nasdaq.com/press-release/biocardia-anticipates-dsmb-feedback-on-interim-data-from-pivotal-phase-3-cardiamp
https://www.nasdaq.com/press-release/biocardia-reports-published-study-showing-helix-biotherapeutic-delivery-system-used
https://www.nasdaq.com/press-release/biocardia-reports-third-quarter-2020-financial-results-and-business-highlights-2020
https://www.nasdaq.com/press-release/published-peer-reviewed-initial-data-from-biocardia-pivotal-phase-3-clinical-trial-of
https://www.nasdaq.com/press-release/biocardia-issued-new-patent-for-delivery-of-cardiac-cell-therapy-through-wrist-artery
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/biocardia-to-present-at-the-ld-micro-500-virtual-conference-on-september-1-2020-2020
https://www.nasdaq.com/press-release/biocardia-reports-second-quarter-2020-financial-results-and-business-highlights-2020
https://www.nasdaq.com/press-release/biocardia-to-conduct-mid-year-conference-call-and-corporate-update-august-13-2020
https://www.nasdaq.com/press-release/ld-micro-announces-preliminary-list-of-presenters-for-the-ld-500-2020-08-05
https://www.nasdaq.com/press-release/biocardia-announces-activation-of-pivotal-trial-studying-cardiamp-cell-therapy-trial
https://www.nasdaq.com/press-release/biocardia-announces-cardiamp-heart-failure-pivotal-trial-continues-with-first-0
https://www.nasdaq.com/press-release/biocardia-announces-cardiamp-heart-failure-pivotal-trial-continues-with-first-patient
https://www.nasdaq.com/press-release/biocardia-announces-pricing-of-%2410-million-public-offering-2020-06-17
https://www.nasdaq.com/press-release/biocardia-reports-first-quarter-2020-financial-results-and-business-highlights-2020
https://www.nasdaq.com/press-release/biocardia-announces-positive-preclinical-results-supporting-investigational-new-drug
https://www.nasdaq.com/press-release/biocardia-announces-fda-recommended-modifications-to-primary-endpoint-for-cardiamp
https://www.nasdaq.com/press-release/biocardia-awarded-new-u.s.-patent-covering-helix-system-for-local-biotherapeutic
https://www.nasdaq.com/press-release/biocardia-announces-litigation-financing-in-the-case-captioned-boston-scientific-corp
https://www.nasdaq.com/press-release/biocardia-reports-2019-financial-results-and-recent-business-highlights-2020-04-09
https://www.nasdaq.com/press-release/biocardia-announces-positive-dsmb-recommendation-to-continue-phase-iii-pivotal
https://www.nasdaq.com/press-release/biocardia-announces-timing-for-prespecified-data-safety-monitoring-board-report-on
https://www.nasdaq.com/press-release/biocardia-announces-fda-clearance-for-morph-dna-deflectable-guide-catheter-2020-01-14
https://www.nasdaq.com/press-release/biocardia-announces-new-u.s.-patent-covering-cardiamp-cell-therapy-and-issuance-of
https://www.nasdaq.com/press-release/biocardia-reports-2019-third-quarter-financial-results-and-business-highlights-2019
https://www.nasdaq.com/press-release/biocardia-to-present-at-dawson-james-securities-5th-annual-small-cap-growth
https://www.nasdaq.com/press-release/biocardia-receives-ce-mark-renewal-for-helix-biotherapeutic-delivery-catheter-and
https://www.nasdaq.com/press-release/biocardia-announces-the-appointment-of-two-new-board-members-2019-10-02
https://www.nasdaq.com/press-release/biocardia-initiates-commercial-release-of-avance-steerable-introducer-designed-to
